What is NovaScan?
Headquartered in Chicago, Illinois, NovaScan operates at the intersection of medical technology and oncology. The company is pioneering a novel point-of-care platform designed to streamline cancer detection and treatment protocols. By focusing on high-precision, cost-effective diagnostic solutions, NovaScan seeks to reduce the barriers to entry for advanced cancer screening, particularly in resource-constrained clinical environments. Their market position is defined by a commitment to science-led innovation, aiming to transform standard oncology workflows into more agile, data-driven processes that prioritize patient healthspan and clinical efficiency.
How much funding has NovaScan raised?
NovaScan has raised a total of $8M across 1 funding round:
Series B
$8M
Series B (2021): $8M with participation from Dipalo Ventures, Builders VC, Stateline Angels, Harvard Business School Alumni Angels of Chicago, BioPacific Investors, and Gore Range Capital
Key Investors in NovaScan
Dipalo Ventures
Dipalo Ventures is a venture capital firm specializing in early-stage, breakthrough deep tech innovations that are transforming the future of energy, climate, and physical AI.
Builders VC
Builders VC is a venture capital firm focused on modernizing antiquated industries by investing in innovative technologies and solutions that reshape complex systems.
Gore Range Capital
Gore Range Capital is a venture capital firm specializing in early-stage healthcare investments, focusing on science-led platforms in precision health and regenerative medicine.
What's next for NovaScan?
With the successful closure of this major strategic investment, NovaScan is poised to scale its operational capabilities and advance its clinical trial pipeline. The company's roadmap focuses on the rigorous validation of its diagnostic platform, ensuring that its technology meets the stringent requirements of modern oncology standards. Furthermore, the influx of capital will likely facilitate the expansion of its research and development team, enabling the firm to refine its core technology and explore new applications within the precision health sector. As NovaScan moves forward, the focus will remain on achieving regulatory milestones and establishing strategic partnerships that can facilitate the widespread adoption of its point-of-care solutions across global healthcare systems.
See full NovaScan company page
